Abstract:With the rise in antimicrobial resistance, there is an urgent need for new classes of antibiotic with which to treat infectious disease. Marinomycin, a polyene antibiotic from a marine microbe, has been shown capable of killing methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus faecium (VREF), as well as having promising activity against melanoma. An attractive solution to the photoprotection of this antibiotic has been demonstrated. Here, we report the identification and analysis of the marinomycin biosynthetic gene cluster (BGC), and the biosynthetic assembly of the macrolide. The marinomycin BGC presents a challenge in heterologous expression due to its large size and high GC content, rendering the cluster prone to rearrangement. We demonstrate the transformation of Streptomyces lividans using a construct containing the cluster, and the heterologous expression of the encoded biosynthetic machinery and production of marinomycin B.

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to identify and heterologously express the biosynthetic gene cluster (BGC) that produces the antibiotic and anticancer drug marinomycin. Specifically, the research aims to: 1. **Identify the biosynthetic gene cluster of Marinomycin**: By analyzing the genomic data of the marine microorganism "Marinispora" CNQ - 140, determine the gene cluster responsible for synthesizing marinomycin. This process includes confirming the role of the key enzyme HMGS (3 - hydroxy - 3 - methylglutaryl - CoA synthase) and verifying its function through insertion - inactivation experiments. 2. **Overcome the challenges in heterologous expression**: Due to the large size, high GC content, and high repeatability of the marinomycin BGC, its cloning and heterologous expression are very difficult. The research team attempts to transfer this gene cluster to a host strain that is easier to ferment and genetically manipulate, such as Streptomyces lividans, in order to achieve heterologous expression and production of marinomycin. 3. **Improve the production efficiency of marinomycin**: By constructing an effective heterologous expression system, provide a platform for future research to optimize and enhance the yield of marinomycin. In addition, this system may also combine synthetic chemistry and synthetic biology methods to develop new analogs. ### Key Background - **Characteristics of Marinomycin**: As a polyene antibiotic, marinomycin exhibits excellent antibacterial activity against methicillin - resistant Staphylococcus aureus (MRSA) and vancomycin - resistant enterococci (VREF) (MIC90 = 0.13 µM), and also has potential anticancer activity against melanoma. - **Photostability issue**: Many polyene compounds are prone to isomerization under light, resulting in poor photostability. For example, the half - life of marinomycin A in sunlight is only 95 seconds, and it is further reduced to 8 seconds under ultraviolet light. However, studies have shown that by encapsulating it in an edible pollen or spore exine, photoisomerization can be effectively prevented, thereby improving its stability. ### Research Significance With the rise of antibiotic resistance, there is an urgent need to develop new antibiotics to deal with infectious diseases. As a promising antibiotic, the successful identification and heterologous expression of the biosynthetic gene cluster of Marinomycin not only helps to understand its biosynthetic mechanism, but also provides an important basis for future drug development.

The Identification and Heterologous Expression of the Biosynthetic Gene Cluster Encoding the Antibiotic and Anticancer Agent Marinomycin

Identification and heterologous expression of the globomycin biosynthetic gene cluster

OSMAC-Based Discovery and Biosynthetic Gene Clusters Analysis of Secondary Metabolites from Marine-Derived Streptomyces globisporus SCSIO LCY30

The antitumor antibiotic mithramycin: new advanced approaches in modification and production

Direct cloning and refactoring of a silent lipopeptide biosynthetic gene cluster yields the antibiotic taromycin A

Auroramycin: A Potent Antibiotic from Streptomyces Roseosporus by CRISPR-Cas9 Activation

Genome mining for macrolactam-encoding gene clusters allowed for the network-guided isolation of β-amino acid-containing cyclic derivatives and heterologous production of ciromicin A

Overproduction of Ristomycin A by Activation of a Silent Gene Cluster in Amycolatopsis japonicum MG417-CF17

Component Optimization of Neomycin Biosynthesis via the Reconstitution of a Combinatorial Mini-Gene-Cluster in Streptomyces fradiae

Biosynthetic Engineering of the Antifungal, Anti-Mrsa Auroramycin

Upregulation and Identification of Antibiotic Activity of a Marine-Derived Streptomyces sp. via Co-Cultures with Human Pathogens

Engineering Streptomyces coelicolor for heterologous expression of secondary metabolite gene clusters

Heterologous Production of Fosfomycin and Identification of the Minimal Biosynthetic Gene Cluster.

Recent Advances in the Heterologous Expression of Biosynthetic Gene Clusters for Marine Natural Products

Cloning, Expression, and Biochemical Characterization of Streptomyces rubellomurinus Genes Required for Biosynthesis of Antimalarial Compound FR900098

Identification of the Actinomycin D Biosynthetic Pathway from Marine-Derived Streptomyces costaricanus SCSIO ZS0073

Genetic Engineering of Streptomyces ghanaensis ATCC14672 for Improved Production of Moenomycins

Heterologous Biosynthesis of Myxobacterial Antibiotic Miuraenamide A

Discovery, Biosynthesis, and Heterologous Production of Streptoseomycin, an Anti-Microaerophilic Bacteria Macrodilactone

Tetarimycin A, an MRSA-active antibiotic identified through induced expression of environmental DNA gene clusters